ओरिस्कन् बायोटेक इन्डिया प्राइवेट लिमिटेड
( कंपनी अधिनियम 1956 के अंतर्गत स्थापित )
Regd. Office : Plot No: C- 80, Ganesh Nagar,Pandav Nagar Complex, New Delhi -110092,
Corporate Office:Plot No: C-31/32, G-3, Ganesh Nagar, Pandav Nagar Complex, New Delhi -110092 , 
Phone No: 011- 22486954
( Click here )

"We are a company registered under the Indian Companies Act 1956 in the year 2006 at New Delhi . At Oriscon Biotech india private limited Our philosophy is to provide economically priced good quality Pharmaceutical Products to the humankind at large. We also believe that there should be no compromise on the health of a human being. Our vision is to become a significant major Pharmaceutical Company in INDIA by providing good quality & affordable economical medicine for the treatment of all types of life threatening disease. "
"We are still in the process of building our own fully integrated, commercial stage bio pharmaceutical company that invents, develops and markets safe and effective small molecule drugs to treat patients with debilitating and life - threatening diseases primarily in cancer , tuberculosis and kala-azar & inflammation . We intend to make & accomplish this through the following innovative strategies:
“We are meticulously making available pharmaceutical products , and constantly improving existing product mix, thereby carving out a niche for ourselves in the field of pharmaceutical marketing in INDIA. We shall provide total customer satisfaction through excellent quality control along with most economically priced Pharmaceutical Products”
Standard Quality policy of the Company :
Your company is dedicated to provide consistently High Quality range of Products in the field of human Health care to the satisfaction of medical community and all consumers at most economical price. This is being achieved by cumulative efforts from the top to bottom by maintaining quality control aimed at Defect prevention rather than Defect Detection".
Cost-effective Marketing strategy :
Your company's track record of development, particularly in the nick area of improved cost-beneficial marketing strategy for latest various drugs molecules is excellent. It also provides a wide variety of generic drugs along with a range of sophisticatedly made drug formulations at most economical price.

All of you must remember," Success depends on your ability to shape the future by anticipating and responding to change. You should also know that you have never been better positioned to achieve this".

Present Status:  ORISCON BIOTECH (I) PVT LTD has been incorporated under the Company's Act on 20th June 2006 having its Registered & Corporate Office in New Delhi. Our business of different procurement agencies since 2006 has been the base of our development, which empowered us to start marketing of our Trade Mark Branded Pharmaceutical Products from Feb 2011 with an investment of Rs. 2 Crores through field force. 
< Marketing through field force in Bihar & Jharkhand > 
At present, we are marketing only 18 products on contract manufacturing (Third Party Basis) in Bihar & Jharkhand through hard core Marketing Personnel, who are having strong potential to generate optimum sales volume in the coming year.
Future Prospects:  We are still in the process of generating additional fund of US $ 2 million (Rs.10 Crores), which is the least amount needed to establish our own Manufacturing Unit and also empowered us to be able to launch our Total Registered Trade Mark’s Brand on all India basis. We can also use this fund for strengthening and streamlining the present marketing position in the coming year.
The Break-even point of manufacturing unit be achieved within the very first operational year by procuring orders from other Marketing Company besides making our own products.
After establishing our own Manufacturing Unit, we can also be able to make available quality medicines at economical price to the needy poor patients, who are unable to treat the life threatening disease like Malaria, Kala-azar, Tuberculosis, Diabetes and other ailments only because of their inability to purchase costly life saving essential medicines, vaccines & other oral antibiotics. Our collective efforts in this regard can generate an additional job opportunity to more than 400 EDUCATED PERSONNEL
In the year under review, our seventh consecutive financial result promise to explore the possibility for establishment of a new manufacturing unit with own R&D Laboratory at the costs of Rs.10 Cr. in Himachal Pradesh. We have in the process of finalising a nodal agency.
WHEREAS the company “Oriscon Biotech (I) Pvt Ltd” decided to finalised / purchase a Pharmaceuticals Manufacturing Unit in the state of Himachal Pradesh at the cost of Rs. Six Crores besides that the company also needs to infuse Further Rs. four crores as a running capital, which is needed to run the factory.
BOARD of  DIRECTORS of company has already authorised Sri Priya Ranjan Shrivastava ( Chairman & Managing Director) to sell the properties described herein “AS IS WHERE IS BASIS AND AS IS WHATEVER IS BASIS” towards satisfaction of the of the company by inviting tenders/bids in a sealed envelope from interested purchasers/bidders on the terms and conditions as mutually decided upon.



To Whom It May Concern
Pl find below the Sale Notice of “SHRI RAM BHAVAN” Prime Commercial Property located @ Main Road, Motihari, East Champaran for all of your kind consideration to a noble cause:
Sale Notice of Immovable properties mortgaged to Oriscon Biotech (I) Pvt Ltd under as a collateral security by BOARD RESOLUTION in this regard. The listed property of company’s Chairman & Managing Director had been mortgaged by its Chairman & Managing Director by Board Resolution to our own company  “Oriscon Biotech (I) Pvt Ltd” as a collateral security provided to company promoter’s investment on dated 20th May_2007, under clause 6,7, 8 & 9 of the Mortgage Resolution there under.
Now we have decided to sale the property for the purchase or establishing our own Pharmaceutical Manufacturing Unit in the name of Oriscon Biotech (I) Pvt Ltd in Himachal Pradesh, which guaranteed to achieve the BREAK-EVEN point within the very 1st operational year, besides it will create further job opportunity to more than 400 Educated Persons. The only reason to arrange the required amount is our inability to arrange a loan either from Financial Institutions of India & Abroad or from individual Venture capitalist around the globe since last three years without any success. Now our company decided to move forward without waiting for the things to be happened in favour of company after exploring the all-possible options to get LOAN.
Whereas, the company “ORISCON BIOTECH INDIA PRIVATE LIMITED”  is the sole proprietor under the future mortgage made in favour of company as a collateral security on behalf of BOARD of DIRECTORS by its Chairman & Managing Director “MR. PRIYA RANJAN SHRIVASTAVA & SMT SHAIL DEVI”. (Bboth are sole proprietor of the property listed below as a legal heir of Late Rameshwar Nath shrivastava – The original registered dead holder of constructed house “SHRI RAM BHAVAN” at District Motihari with absolute title & mutation right since the year 1953).
While it is still early days of organisational development, despite that your company is making solid progress.
Your Directors are happy to recommend a dividend of 14% (inclusive of dividend tax). The right shares issued during the period April to March ( 2012 - 13 ) are also qualify for full year's dividend. The Company's financial results for the financial year ended 31st March 2013 are as summarised: 
The present Authorised share capital of the company is Rs.40,00,000/-(Rupees Forty Lacs only) divided into 4,00,000 (Four Lacs) equity shares of Rs.10/- (Rupees Two only) each. Your Board recommends that to enhance the Equity base for growth and expansion plans of the Company.
The Authorised Capital of the Company be increased from Rs.40,00,000/-(Rupees Forty Lacs only) divided into 4,00,000 (Four Lacs) equity shares of Rs.10/- (Rupees Ten only) each to Rs.2,00,00,000/-(Rupees Two crore only) divided into 20,00,000 (Twenty Lacs) Equity shares of Rs.10/- (Rupees Ten only) each. It is therefore, proposed to increase the authorized capital from Rs.40,00,000/-( Rupees Forty Lacs only) to Rs.2,00,00,000/- (Rupees Two crore only) by creation of 16,00,000 (Sixteen Lacs) New equity shares of Rs.10/- (Rupees Ten only) each. Consequently, Clause V of the Memorandum of Association and Article 3 (a) of the Articles of Association of the Company has been altered.
A Copy of Memorandum and Articles of Association of the Company together with the proposed alteration will be made available for inspection by the Members of the Company at its registered office between 11:00 a.m. and 1:00 p.m. on any working day of the Company until the date of Annual General Meeting.
In terms of the provisions of Section (s) 16, 31and 94 consent of the Members is required for any alteration in Memorandum and Articles of Association of the Company. The Board recommends the Resolutions for your approval.
Under section 293(1)(d) of the Companies Act, 1956, the Board of Directors cannot except with the consent of the Company borrow moneys apart from temporary loans obtained from the Company's bankers in the ordinary course of business in excess of the aggregate of paid-up capital and free reserves of the Company, that is to say, reserves not set apart for any specific purpose. 
The members of the Company at the Extra-ordinary General meeting held on April 20, 2012  authorised  (Priya Ranjan Shrivastava –CMD) by Special resolution of Board of Directors of the Company to borrow up to a limit of Rs. 2 crores. In view of increased volume of business envisaged in the forthcoming months, it is proposed to continue the authorisation of the Board to Priya Ranjan Shrivastava –CMD  for borrowing limit up to Rs2 crores and for this purpose approval under Section 293(1)(d) of the Act is extended in next financial year. 
Your Company is dealing in Institutional supply of Pharmaceuticals Generic products with the various procurement departments. 
Every Company has to concentrate on both fronts the present to continue its operation successfully at the current level in the stronghold area for generating operational profit ,and the future to prepare itself for the challenges lying ahead. Since Bihar is considered a Gold Mine for Pharmaceutical Business due to very high rate of consumption of medicine by per capita population. This is the reason that all Pharma Companies have started their marketing venture from Bihar. Therefore, this aspects of marketing is on our plus side ; considering the facts that promoters of this company are having eighteen years of Marketing Experience of each and every town of Bihar & Jharkhand. Our company has set forth to achieving Rs.2 Crores sales in the year (2013-14) with a team of 25 Medical Representatives, Two Zonal Sales Managers & Five Regional Managers.
One of the director of the Company Mr. Abinash Chandra Verma are being disqualified on charges of committing forgery & cheating.
Mr.Priya Ranjan Shrivastava - as a Chairman & Managing Director, Mr.Kamlendra Kumar - as a Joint Managing Director, Dr.Amaresh Kumar Singh - as a Director Human Resources, Jugal Sah - as Investment Committee Director & Mr. Manoj Kumar Thakur as a Legal Advisor of the Company. Dr. Bijay Kumar Gupta as Director Product Research & Mr. Mithilesh Kumar as Director Welfare Committee. 
a)     In case of Mr. Abinash Chandra Verma who was entrusted as Director Audit Committee had misused his position by way of committing forgery & cheating during his tenor at New Delhi. He had also done Embezzlement of company’s cash kept in the office on different occasions by using smart technique of falsifying the records by removing a small amount of money and made false entry in the record the register to look it technically correct. On several occasion in the past he was requested to appear before enquiry committee at our corporate office in New Delhi & last date was fixed on 28/06/2013 to attend along with Cash Register & Receipt for the year (2011-12) but he is still avoiding to face the disciplinary committee. The Board of Directors has authorised Mr. Priya Ranjan Shrivastava (CMD) to deliver The Last Notice personally during stay at Motihari to Mr. Abinash Chandra Verma & Company will initiate legal proceeding after receiving status report on forgery & cheating done  Mr. Abinash Chandra Verma.

b)    We are sorry to inform all of you that two of our Esteemed Directors named Sri Uday Kant Thakur & Sri Kunal Mishra are no more in this world, their sudden demise is irreparable loss to our extended family of  the company and we all pay homage to the departed soul .

There is a clear procedure for appointments to the Board. Such appointments are formal and transparent and a matter for the Board as a whole. There is a clear division of responsibility to ensure a balance of power, such that no one individual has unfettered powers of decision-making. At 31 March 2013, the Board comprised Non-Executive and Executive Directors who, with their experience, knowledge and skill, add to the successful operation of the Company.
Chairman and Managing Director –
Managing the Executive Committee is the responsibility of the whole time Director, Mr. Priya Ranjan Shrivastava.
Shareholder Representation :
*    Mr. Priya Ranjan Shrivastava,
*    Mr Kamlendra Kumar,
*    Mr.Jugal Sah,
*    Mr. Mithilesh Kumar,
*    Dr. Bijay Kumar Gupta ,
*    Dr. Amaresh Kumar Singh
Audit Committee:
Mr Tarun Kumar (Advocate), although he is not a Board Member
Investment Committee:   
Mr. Jugal Sah
Remuneration Committee:
Mr Tarun Kumar , although he is not a Board Member.
Transformation Committee: 
*    Dr.Amaresh Kumar Singh,
*    Mr. Manoj Kumar Thakur
However when a new vendor is to be approved as the situations demand Oriscon Biotech Private Limited has written down procedures as per law for approval of new vendors. Stability study of the product and its quality is done when there is a change in manufacturer / vendor / supplier of critical materials like active ingredients of pharmaceutical molecule , Primary Packing materials & any critical equipments.
All finished products are tested to the specified standards as per norms given in specification. All the products of our company are subjected to chemical and microbiological analysis for total counts of microbes and absence of pathogenic organisms. The products are released for dispatch after compliance of the products to the specified standards.
None of the employees of the Company is in receipt of remuneration drawing in excess of limits prescribed under Section 217 (2A) of the Companies Act, 1956 read with (Particulars of Employees) Rules, 1975 as amended and hence no information is furnished thereto.
The Board of Directors has decided to take further steps to convert the same into a Public Limited Company in near future.

Cordial industrial relations prevailed during the year.
Your Company has not accepted any public deposit during the period under review.
M/S  JHA SHAILENDRA & ASSOCIATES., CHARTERED ACCOUNTANTS, NEW DELHI , were appointed as first-auditors of the Company and their term of office expires at the ensuing Annual General Meeting. They, being eligible, offer themselves for appointment. A Certificate under Section 224 (1B) of the Companies Act, 1956 has  been obtained from them.
In terms of Section 217(2AA) of the Companies Act, 1956, your directors confirm:
That in the preparation of the annual accounts, the applicable accounting standards had been followed:
that the applicable accounting policies have been consistently followed and that they had made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;
That they had taken proper and sufficient care for the maintenance of adequate accounting records, in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; and
That they had prepared the annual accounts on a going concern basis.
Your Company has no activity relating to conservation of energy or technology absorption. Your Company did not have any foreign exchange earnings or outgo during the year.
Not Applicable
The foreign exchange earnings/outgo of the Company for the year under review was nil.
The Directors take this opportunity to express their appreciation for the cooperation received from the State Government of New Delhi, the Company's Bankers, valuable customers and others concerned with the Company.
Your Directors, also thank the executives, staff and employees of the Company for their valuable services and support during the year.
By Order of the Board, 
For Oriscon Biotech (India) Private Limited
( Priya Ranja Shrivastava )
 Chairman & Managing Director